Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire November 11, 2025 SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on November 10, […]

MannKind to Present at the Jefferies Global Healthcare Conference GlobeNewswire November 11, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present and share updates during the Jefferies London Healthcare

After months of anticipation, composer Veronika Wu has completed the recording of her latest album Under the Ocean: Mermaid – A Cello Suite, a deeply immersive six-movement work inspired by the voices that rise from beneath the sea. The album, performed by acclaimed cellist Tomoki Tai and recorded at SOUND INN STUDIOS in Tokyo, Japan,

(NASDAQ:MGX), New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-owned MGX-001 hemophilia A program; pre-IND meeting for MGX-001 expected in 4Q 2025 with IND/CTA submissions expected in 4Q 2026 Organizational restructuring reduced workforce by 25%; Capital allocation strategy anticipated to extend cash

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates GlobeNewswire November 11, 2025 New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-owned MGX-001 hemophilia A program; pre-IND meeting for MGX-001 expected in 4Q 2025 with IND/CTA

B. Riley Financial, Inc. (Nasdaq: RILY) (the “Company”) today announced that the Company will change its name to BRC Group Holdings, Inc. (“BRC”), effective on January 1, 2026. BRC Group Holdings will continue to be a diverse portfolio of companies, including financial services, telecom, and retail, and investments in equity, debt and venture capital. Bryant

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.jpg — Jefferies Global Healthcare Conference. Fireside chat on Tuesday, November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London — Piper Sandler 37th Annual Healthcare Conference. Fireside chat on Tuesday, December 2,

(NASDAQ:MGX), MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary

(NASDAQ:ASTE), CHATTANOOGA, Tenn., Nov. 11, 2025 (GLOBE NEWSWIRE) — Astec Industries, Inc. (NASDAQ:ASTE) announced today it will participate in the Stephens Investment Conference (NASH2025) on Tuesday, November 18, 2025, in Nashville, Tennessee. Jaco van der Merwe, President and Chief Executive Officer, Brian Harris, Chief Financial Officer, and Stephen C. Anderson, Senior Vice President of Administration

(NYSE MKT:STXS), ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory